AI-assisted, human-published
10/25/2024 /Funding Events
Agomab Therapeutics Secures $89 Million in Series D Financing
Agomab Therapeutics NV secures $89 million in Series D financing round with participation from new investors Sanofi and Invus. The funding will be utilized to advance clinical development of lead candidates for fibrostenosing Crohn’s disease and idiopathic pulmonary fibrosis as well as for developing potential novel therapies.
AI-assisted, human-published
Latest headlines
-
-
-
Stay connected!
If you have a serious, bonafide inquiry into the VentureCapital.com or PrivateEquity.com domain names, please contact us here
©2023 VentureCapital.com